Department of Thoracic and Cardiovascular surgery, Armed Forces Capital Hospital, Seongnam, Republic of Korea.
Supportive Care Center/ Department of Family Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; Department of Digital Health, SAIHST, Sungkyunkwan University, Seoul, Republic of Korea.
Lung Cancer. 2019 Oct;136:115-121. doi: 10.1016/j.lungcan.2019.08.025. Epub 2019 Aug 24.
With advances in lung cancer treatments, the number of lung cancer survivors has increased. As cardiovascular diseases (CVD) are some of the major causes of non-cancer deaths, CVD management is an integral part of cancer survivorship care. However, there is sparsity of data on cardiovascular risk in lung cancer survivors who underwent lung cancer surgery. We aimed to compare the incidence of CVD between lung cancer survivors and the general non-cancer population.
Using the Korean National Health Insurance Service Database, we selected 20,458 patients who underwent surgery for lung cancer between 2007 and 2013. Study outcome variables were coronary heart disease (CHD), myocardial infarction (MI), ischemic stroke (IS), and death. Patients were followed until 2016.
A total of 20,458 lung cancer patients undergoing lung cancer surgery were compared to 27,321 non-cancer control subjects. Lung cancer survivors showed a greater risk for all cardiovascular (CV) events (adjusted hazard ratio [aHR] = 1.27, 95% confidence interval [CI]: 1.19-1.36), CHD (aHR = 1.26, 95% CI: 1.16-1.36), and IS (aHR = 1.22, 95% CI: 1.07-1.39). Chemotherapy and radiotherapy were associated with an increased risk of CV events, CHD, and MI. Lung cancer survivors who were CV event-free for one year, and up to three years, were still at a higher risk for all CV events compared to the non-cancer control population.
Lung cancer survivors showed an increased risk of CHD and IS compared with the general non-cancer population. Therefore, paying careful attention to cardiovascular risk in lung cancer survivors is suggested, especially for those who receive chemotherapy and/or radiotherapy, in order to ensure both early and long-term survivorship.
随着肺癌治疗的进展,肺癌幸存者的数量有所增加。由于心血管疾病(CVD)是导致非癌症死亡的主要原因之一,因此 CVD 管理是癌症生存者护理的一个组成部分。然而,接受肺癌手术的肺癌幸存者的心血管风险数据很少。我们旨在比较肺癌幸存者和一般非癌症人群的 CVD 发生率。
使用韩国国家健康保险服务数据库,我们选择了 2007 年至 2013 年间接受肺癌手术的 20458 名患者。研究结果变量为冠心病(CHD)、心肌梗死(MI)、缺血性中风(IS)和死亡。患者随访至 2016 年。
共有 20458 例接受肺癌手术的肺癌患者与 27321 例非癌症对照患者进行了比较。肺癌幸存者发生所有心血管(CV)事件的风险更高(调整后的危险比[aHR] = 1.27,95%置信区间[CI]:1.19-1.36)、CHD(aHR = 1.26,95% CI:1.16-1.36)和 IS(aHR = 1.22,95% CI:1.07-1.39)。化疗和放疗与 CV 事件、CHD 和 MI 的风险增加相关。对于所有 CV 事件,在一年及三年无 CV 事件的肺癌幸存者仍比非癌症对照组人群的风险更高。
与一般非癌症人群相比,肺癌幸存者患 CHD 和 IS 的风险增加。因此,建议对肺癌幸存者的心血管风险进行仔细关注,特别是对于接受化疗和/或放疗的患者,以确保早期和长期生存。